In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease
- PMID: 8356053
- PMCID: PMC47178
- DOI: 10.1073/pnas.90.16.7543
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease
Abstract
Protease inhibitors are another class of compounds for treatment of human immunodeficiency virus (HIV)-caused disease. The emergence of resistance to the current anti-HIV drugs makes the determination of potential resistance to protease inhibitors imperative. Here we describe the isolation of an HIV type 1 (HIV-1) resistant to an HIV-protease inhibitor. Serial passage of HIV-1 (strain RF) in the presence of the inhibitor, [2-pyridylacetylisoleucylphenylalanyl-psi (CHOH)]2 (P9941), failed to yield a stock of virus with a resistance phenotype. However, variants of the virus with 6- to 8-fold reduced sensitivity to P9941 were selected by using a combination of plaque assay and endpoint titration. Genetic analysis and computer modeling of the variant proteases revealed a single change in the codon for amino acid 82 (Val-->Ala), which resulted in a protease with lower affinity and reduced sensitivity to this inhibitor and certain, but not all, related inhibitors.
Similar articles
-
In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.J Virol. 1995 Sep;69(9):5228-35. doi: 10.1128/JVI.69.9.5228-5235.1995. J Virol. 1995. PMID: 7636964 Free PMC article.
-
Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.J Virol. 1995 Apr;69(4):2148-52. doi: 10.1128/JVI.69.4.2148-2152.1995. J Virol. 1995. PMID: 7884862 Free PMC article.
-
A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A.Antimicrob Agents Chemother. 1997 Mar;41(3):515-22. doi: 10.1128/AAC.41.3.515. Antimicrob Agents Chemother. 1997. PMID: 9055985 Free PMC article.
-
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.AIDS Rev. 2008 Jul-Sep;10(3):131-42. AIDS Rev. 2008. PMID: 18820715 Free PMC article. Review.
-
HIV protease: a novel chemotherapeutic target for AIDS.J Med Chem. 1991 Aug;34(8):2305-14. doi: 10.1021/jm00112a001. J Med Chem. 1991. PMID: 1875332 Review. No abstract available.
Cited by
-
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor.J Virol. 1994 Mar;68(3):2016-20. doi: 10.1128/JVI.68.3.2016-2020.1994. J Virol. 1994. PMID: 8107264 Free PMC article.
-
Structure of equine infectious anemia virus proteinase complexed with an inhibitor.Protein Sci. 1996 Aug;5(8):1453-65. doi: 10.1002/pro.5560050802. Protein Sci. 1996. PMID: 8844837 Free PMC article.
-
A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.J Virol. 1998 Mar;72(3):2335-40. doi: 10.1128/JVI.72.3.2335-2340.1998. J Virol. 1998. PMID: 9499094 Free PMC article.
-
In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.J Virol. 1996 Mar;70(3):2038-43. doi: 10.1128/JVI.70.3.2038-2043.1996. J Virol. 1996. PMID: 8627733 Free PMC article.
-
Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.J Virol. 1994 Jan;68(1):233-9. doi: 10.1128/JVI.68.1.233-239.1994. J Virol. 1994. PMID: 8254733 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
